Acta Chimica and Pharmaceutica Indica
ISSN: 2277-288X

Modern Chemistry Online Journals

Tumor hypoxia has been sought after as a disease sedate objective for over 30 years, most quite utilizing bioreductive (hypoxia-enacted) prodrugs that target antineoplastic specialists to low-oxygen tumor compartments. In spite of convincing proof connecting hypoxia with treatment obstruction and unfavorable anticipation, various such prodrugs have as of late neglected to exhibit adequacy in urgent clinical preliminaries; a result that requests reflection on the revelation and advancement of these mixes. In this survey, we talk about an unmistakable separate between the pathobiology of tumor hypoxia, the pharmacology of hypoxia-initiated prodrugs and the way wherein they have been taken into clinical turn of events. Hypoxia-initiated prodrugs have been assessed in the way of expansive range cytotoxic operators, yet a developing collection of proof recommends that their movement is probably going to be reliant on the fortuitous event of tumor hypoxia, articulation of explicit prodrug-enacting reductases and inborn affectability of harmful clones to the cytotoxic effector. Hypoxia itself is profoundly factor between and inside individual tumors and isn't treatment-restricting in all malignancy subtypes. Characterizing prescient biomarkers for hypoxia-initiated prodrugs and defeating the specialized difficulties of measuring them in clinical settings will be basic to sending these operators in the period of customized disease medication. 

High Impact List of Articles

Relevant Topics in Chemistry

Awards Nomination

Table of Contents

Google Scholar citation report
Citations : 968

Acta Chimica and Pharmaceutica Indica received 968 citations as per Google Scholar report

Citation image

Indexed In

  • Open J Gate
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Cosmos IF
  • Scientific Indexing Services (SIS)
  • ICMJE

View More

For Authors

For Librarians

Flyer

Open Access Journals